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Abstract (350 words max, currently 350 words) 
Background: Parkinson’s affects approximately 145,519 people in the UK. Speech 
impairments are common with a reported prevalence of 68%, which increase physical and 
mental demands during conversation, reliance on family and/or carers, and the likelihood of 
social withdrawal reducing quality of life. In the UK, two approaches to speech and language 
therapy (SLT) intervention are commonly available: NHS SLT or Lee Silverman Voice 
Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice 
typically consisting of 6–8 weekly sessions; LSVT LOUD® comprises 16 sessions of 
individual treatment with home-based practice over 4 weeks. The evidence-base for their 
effectiveness is inconclusive. 
Methods/Design: PD COMM is a phase III, multicentre, 3-arm unblinded randomised 
controlled trial.  546 people with idiopathic Parkinson’s, reporting speech or voice problems 
will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or 
who have received SLT for speech problems in the previous 2 years. Following informed 
consent and completion of baseline assessments, participants will be randomised in a 1:1:1 
ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-
generated programme, using a minimisation procedure with a random element, to ensure 
allocation concealment. Participants randomised to the intervention groups will start 
treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation.  
Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes 
include: VHI subscales, Parkinson's Disease Questionnaire-39; Questionnaire on Acquired 
Speech Disorders; EuroQol-5D-5L; ICECAP-O; resource utilisation; adverse events and 
carer quality of life. A mixed methods process and health economic evaluations will take 
place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 
12 months after randomisation. 
The trial started in December 2015 and will run for 77 months. Recruitment will take place in 
approximately 42 sites around the UK. 
Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech 
or voice problems in people with Parkinson’s compared to no SLT. It will further test 
whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-
effectiveness of both interventions. 
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Trial Registration: International Standard Randomised Controlled Trials Number (ISRCTN) 
Registry ID: 12421382, registered on 18th April 2016. 
Keywords (3 – 10 Keywords): Idiopathic Parkinson’s Disease, Lee Silverman Voice 
Treatment, Speech and Language Therapy, Randomised Controlled Trial, dysarthria. 
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Background 
In prevalence and years lived with disability, Parkinson’s is the fastest-growing neurological 
disorder in the world,(1) and it affects approximately 145,519 people in the UK. Parkinson’s 
is a complex progressive condition with a range of motor and non-motor symptoms.(2) 
Speech impairments are common in the Parkinson’s population with a reported prevalence of 
68% for patient-perceived problems and 71% for listener-rated speech impairment.(3) In a 
study of 125 participants with  Parkinson’s,(4) 38% placed speech among their top four 
concerns, and in another study, 29% of participants (5) reported speech problems to be 
among their greatest present difficulties. Miller et al.,(6)  noted how changes in 
communication led to increased physical and mental demands during conversation, an 
increased reliance on family members and/or carers, and an increased likelihood of social 
withdrawal. The speech of people with  Parkinson’s is often perceived as sounding quiet and 
imprecise, creating a potential social barrier to communication.(7) A qualitative study 
involving 24 people living with Parkinson’s identified problems with speaking as an activity. 
The interviewees reported having to think more about speaking; weighing up the value versus 
the effort of speaking; having negative feelings about speaking; finding speaking is 
influenced by different people and places; and having to adjust to the effect on speaking of 
the disease progression and medication.(8) Overall, impairments of speech have been 
recognised to reduce the quality of life of people with Parkinson’s.(7, 9, 10)  
 
Speech and language therapy for speech difficulties in people with Parkinson’s in the UK 
aims to improve communication.  Some therapy approaches engage the person with 
Parkinson’s in exercises to improve motor skills, others support the communication 
partnership between the person with Parkinson’s and their communication partner, while 
others consider augmentation of or alternative means of communication.  Following 
assessment and discussion with the person with Parkinson’s, an individually tailored therapy 
plan is developed to address their needs and that of their family. For the purposes of the PD 
COMM trial, any of the above will be included in the intervention arm called “standard NHS 
SLT”. This ‘standard NHS SLT’ is distinct from the other trial intervention arm which 
comprises LSVT LOUD®(11).  Within the PD COMM trial two types of speech and 
language therapy will be assessed: standard NHS SLT and LSVT LOUD®(11) against a no 
SLT control. 
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Standard NHS SLT can include any of the above with the therapist selecting from 
multifaceted therapy components and tailoring these to the needs of the individual, their 
impairment and participation targets and within the constraints for that particular clinical 
service. (6) Typically weekly sessions over 6 – 8 weeks are prescribed, either individually or 
in groups.(13, 14).  LSVT LOUD® differs to standard NHS SLT in that it is a more 
prescriptive therapy. The focus of LSVT® is to “think loud”; improving phonation and vocal 
loudness through better vocal fold adduction(12) over an intervention lasting16 sessions. The 
single focus and intensive delivery is used to ‘recalibrate’ the patient, so they recognise that a 
voice which sounds too loud to them is necessary for them to be understood by other people.  
LSVT LOUD® is increasingly being used in the NHS, but in the context of PD COMM, 
standard NHS SLT excludes the delivery of   LSVT®.   
 
A Cochrane review of SLT versus no intervention (last search date 11th April 2011) 
identified three randomised controlled trials (RCTs) of differing SLT interventions versus no 
intervention (n=63). (15) The SLT evaluated varied from: 10 hours over 4 weeks of 
individual therapy focussing on prosodic features of pitch and volume reinforced by visual 
feedback;(16) 16 hours over 4 weeks of LSVT(11); and 35 – 40 hours over 2 weeks 
improving loudness and pitch variation, respiration, voice production and intelligibility 
reinforced by visual feedback primarily in a group setting.(17) The review authors concluded 
that while outcome measures improved following SLT, the small participant numbers, low 
RCT quality and the possibility of publication bias, meant that the efficacy of SLT for 
progressive dysarthria in Parkinson’s against a placebo or no intervention could not be 
confirmed or refuted. In another Cochrane review of six trials comparing different theoretical 
approaches to SLT provision for people with dysarthria (n=159).(18) All six trials assessed 
intelligibility and almost all of the results were not statistically significant. The exception to 
this was for one of the three types of perceptual ratings of speech recordings made in the 
study by Halpern et al.,(19) for which LSVT gave the greater improvement (n = 14). Herd et 
al.,(18) concluded that the small number of participants examined, the low methodological 
quality of the trials evaluated, and the possibility of publication bias resulted in an inability to 
determine superiority of any one type of SLT over another. Since these reviews were 
published, two further RCTs have been reported: the PD COMM Pilot(14) (described below) 
and a trial comparing LSVT LOUD® with LSVT ARTIC® (a second type of  LSVT 
focussing on increased movement amplitude directed predominately to orofacial‐articulatory 
system, but with the same dosing schedule and intensity) with a no SLT intervention control 
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in people with Parkinson’s and healthy controls.(20) The latter trial included 64 people with 
Parkinson’s and measured sound pressure level (SPL) differences and a modified 
Communications Effectiveness index (CETI-M) at 1 and 7 months. LSVT LOUD® 
significantly increased SPL at 1 and 7 months compared to LSVT ARTIC® and Control. 
Both LSVT groups also showed a greater improvement than control in CETI-M at 1 month, 
but this difference was not maintained at 7 months. A pilot trial (PD COMM Pilot) 
randomised 89 people with speech problems into a three arm, assessor blinded randomised 
controlled trial (RCT) to assess the feasibility and to inform the trial design of a full-scale 
RCT (15). Participants were randomised to either LSVT LOUD®, standard NHS SLT or no 
intervention control in a 1:1:1 ratio. The pilot trial showed a trend towards improvement in 
the LSVT LOUD® and SLT groups over the control group at 3 months, but the findings were 
not powered to give a definitive answer. 
The PD COMM trial design was informed by our PD COMM Pilot trial, which was funded 
by The Dunhill Medical Trust. The PD COMM trial is funded by the UK National Institute 
for Health Research Health Technology Assessment programme (10/135/02). Further support 
was provided by Prof Lori Ramig in the form of free LSVT LOUD® training.  The protocol 
is reported using the SPIRIT(21) and TIDieR(22) guidelines.  
Methods/Design 
The PD COMM Trial protocol can be found on: 
https://www.birmingham.ac.uk/research/activity/mds/trials/bctu/trials/pd/PD-
COMM/investigators/documentation.aspx (last accessed 10th September 2019). The trial 
received ethical approval on 7th December 2015 by the West Midlands NHS Research Ethics 
Committee (15/WM/0443), with protocol version 4.0 (14th November 2018) currently in 
effect (see amendment section for details). The project is sponsored by the University of 
Birmingham (Research Governance Team, University of Birmingham, Birmingham, B15 
2TT). 
PD COMM is a multicentre, phase III, three-arm unblinded RCT where participants are 
randomised in a 1:1:1 ratio to a no-intervention control group, NHS SLT or LSVT LOUD®.   
The primary objective of the trial is to evaluate the clinical and cost-effectiveness of the two 
types of SLT versus no SLT treatment (no SLT control) for people with Parkinson’s, but the 
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trial will also compare the two types of SLT (LSVT LOUD® versus standard NHS SLT). 
Therefore, there will be three comparisons within the trial: 
1. LSVT LOUD® versus no SLT control 
2. Standard NHS SLT versus no SLT control 
3. LSVT LOUD® versus standard NHS SLT 
 
Patient reported measures are being used to assess the participant’s perception of how their 
voice impacts on daily activities and their quality of life to assess clinical effectiveness. The 
quality of life of carers will also be assessed, and a cost-effectiveness analysis will be 
performed.  
Participant Characteristics 
People will be eligible to be recruited into the trial if they have idiopathic Parkinson’s as 
defined by the 1988 UK PDS Brain Bank Criteria;(23) they, or their carer, report problems 
with speech or voice when asked and they have no signs of dementia - typically this is 
determined by the person with Parkinson’s clinician as per local practice. Furthermore, they 
must not have evidence of laryngeal pathology including: vocal nodules, a history of vocal 
strain or previous laryngeal surgery as such patients may not be suitable for LSVT LOUD®; 
and have not received SLT for speech or voice related problems in the past 2 years, as there is 
some evidence that benefits of LSVT may persist for 24 months.(12)   
 
Identification, Recruitment and Randomisation 
The trial is designed to align with routine care thus minimising the burden for people with 
movement difficulties. Participants will usually be identified during routine clinic 
appointments with their clinician or Parkinson’s Specialist Nurse who will inform potentially 
eligible patients of the trial and provide a copy of the patient information sheet (PIS). The 
patient will be given time to review the PIS and/or go through it with a member of the team, 
typically the research nurse, and will be given the opportunity to ask questions. Given the low 
risk nature of the trial, and the mobility limitations of the population, participants may join 
the trial on the same day that they discuss the trial and receive the PIS or may come back at a 
later date if they prefer.  
 
Following informed consent and completion of the baseline assessment and questionnaires, 
the participant can be randomised into the trial. Prior to randomisation, the team will check 
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the availability of speech and language therapists at that site. Randomisation may be deferred 
if the SLT intervention cannot be initiated within the set time frames – however the 
participant’s baseline questionnaire needs to be completed within 2 weeks prior to 
randomisation, so this should be factored in to any planned delay of a patient’s 
randomisation. Typically the research nurse, will obtain informed consent and randomise the 
patient into the trial and liaise with the speech and language therapist to ensure SLT (should 
they be randomised to therapy) starts within the required timeframe.  
 
Following informed consent and completion of all baseline data collection, participants will 
be randomised at the level of the individual via a central secure web-based randomisation 
system at the Birmingham Clinical Trials Unit (BCTU) to ensure concealment of next 
treatment allocation. Typically randomisation will be performed by the research nurse. The 
randomisation process will use a minimisation procedure with a random element. The 
following minimisation variables will be used:  
 age (≤59, 60-70, >70 years);  
 disease severity measured using the Hoehn & Yahr(24) staging (1.0 - 2.5, 3 - 5); and 
  severity of speech measured using the Voice Handicap Index (VHI)(25) total score 
(≤33, mild 34-44, moderate 45-61, severe >61).  
 
Once randomised into the trial, NHS SLT should start within 4 weeks and LSVT LOUD® 
should start within 7 weeks to enable the intervention to be completed prior to the primary 
end point (at 3 months post-randomisation). The trial will last for 77 months. Recruitment 
will take place in approximately 42 sites around the UK (see table 1). 
[Insert table 1 here] 
Interventions 
Standard NHS SLT 
Standard NHS SLT is not prescriptive and does not have standard content or dosage. It is 
therefore not possible to predict the number of sessions that will be provided. A survey of 
current UK SLT practice for Parkinson’s (13) reported a median dose of 6 sessions delivered 
over 42 days. The PD COMM Pilot trial found the median dose to be 6 sessions (range 1 – 
14) over an average of 9.6 weeks (standard deviation 6.1 weeks).(14) 
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Treatment is typically tailored to the individual’s level of difficulty or dysarthria severity and 
their interests as individual need and clinical constraints. Treatment will be individualised to 
suit each participant’s needs as per local practice. It may include impairment based 
interventions, compensatory interventions and augmentative and alternative communication 
(ACC) strategies aimed at improving communication and participation. The participant’s 
family/carer(s) may be involved. Therefore, the NHS SLT arm will encompass any SLT 
interventions that are not LSVT LOUD® as per the LSVT LOUD® protocol.  
 
Treatments targeted at impairment level may include exercises focused on improving 
capacity, control and co-ordination of respiration, techniques for improving phonation 
intensity and co-ordination with respiration (but not LSVT LOUD®), and exercises to 
improve the range, strength and speed of the articulatory muscles.(16, 17) Behavioural 
therapy may include interventions aimed at reducing prosodic abnormality(27, 28) such as 
exercises targeting pitch, intonation, stress patterns, and volume variation,(16, 17, 27-29) and 
techniques to address the overall rate of speech(16, 17) including the use of therapeutic 
devices such as pacing boards.(30, 31) AAC strategies such as topic and alphabet 
supplementation through communication books and boards may be employed,(26) along with 
AAC devices such as voice amplifiers, delayed auditory feedback systems and masking 
devices.(32-34) The practice of pitch limiting voice treatment(35) may also be utilised within 
the standard SLT intervention.   
 
The above methods may include techniques used in LSVT LOUD® e.g. vocal intensity 
exercises, but will be distinct by the individualised treatment, other SLT strategies, lower 
intensity of delivery and (potentially) the use of group intervention. 
 
Dose will be determined by the therapist reflecting participants’ individual needs, but the 
duration is unlikely to exceed twelve weeks of treatment. Sessions will be conducted by a 
suitably trained speech and language therapist or therapy assistant on a one to one or group 
basis per participant need and local practice. Sessions may take place in out-patient clinics, 
the participant’s home or in the community.  
 
LSVT LOUD® 
The LSVT LOUD® intervention is prescriptive and consists of four 50 minute sessions per 
week delivered over four weeks.(36) Each session follows a similar structure: 25 minutes of 
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repeated and intensive maximum effort drills, and 25 minutes of high effort speech 
production tasks.(36) Participants will also be set 5 to 10 minutes of home-based practice 
tasks on treatment days, and up to 30 minutes of home-based practice tasks on non-treatment 
days.(37)  
 
Content will consist of repeated repetitions of sustained “ah” phonation, maximum 
fundamental frequency range high and low pitch glides, and functional sentence repetition for 
the first half of each session, and exercises using speech production hierarchy that progresses 
throughout duration of the treatment programme (single word, phrases, sentences, paragraph 
reading, conversation) during the second half of the sessions.(37) Throughout all of the 
sessions, the focus of the intervention will be to “think loud”, maintaining the vocal loudness 
produced during vowel phonation throughout all other tasks during the treatment.(36) 
 
Sessions will be conducted by a suitably trained speech and language therapist or therapy 
assistant on a one to one basis. Sessions may take place in out-patient clinics, the 
participant’s home or remotely using tele-LSVT software. Once the exercises have been 
established, LSVT LOUD® may be delivered using the LSVT companion software for a 
proportion of the time, in line with local practice. 
 
Control 
The control group will not receive any SLT for their speech for 12 months, unless it becomes 
clinically necessary. At the end of 12 months, participants will be treated per local practice. If 
the participant needs SLT prior to 12 months, with their continued consent, they will remain 
in the trial and be followed up as usual and included in the trial analyses. 
 
Participants are free to withdraw from the trial at any time or they may agree to continue in 
the trial but not comply with treatment. In the latter case they will continue to be followed up 
as per the protocol and the data will be analysed according to the group that they were 
randomised to (intention to treat).  
 
Outcomes 
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Following the analysis of PD COMM Pilot, the design of the trial was refined to reduce the 
burden on participants and Speech and Language Therapists by excluding the battery of vocal 
assessments and voice related quality of life(38) questionnaire. 
Primary Outcome 
The primary outcome measure for the trial is patient reported Voice Handicap Index 
(VHI)(25) total score at 3 months.  
 
There was some discussion about the choice of primary outcome, as most previous trials had 
used vocal loudness. The VHI was chosen given it is patient-reported, brief, (and from the 
pilot trial) well completed, and in our view better reflects the focus of the trial. Alongside the 
VHI, a battery of patient-reported outcomes (PROs; see secondary outcomes) are being 
collected, which cover a range of other important areas.  In the pilot trial, extensive vocal 
assessments were carried out alongside the PROs. We decided not to undertake vocal 
assessments within the PD COMM trial as 1). the additional time involved was prohibitive; 
2). there was concern that since one of the trial interventions (LSVT LOUD®) specifically 
focussed on vocal loudness that the results might be skewed in favour of this intervention; 
and 3). the focus of the trial was on the participants self–perception of functional 
communication rather than vocal loudness.  
 
Secondary Outcomes 
Patient reported: Subscales of the VHI;(25) Parkinson's Disease Questionnaire-39 (PDQ-
39);(39) Questionnaire on Acquired Speech Disorders (QASD);(40) EuroQol-5D (5 level 
version);(41) ICEpop Capabilities measure for older people (ICECAP-O);(42) resource 
utilisation; and adverse events.  
 
Carer reported: Carer quality of life (Parkinson’s Disease Questionnaire - Carers).(43)  
 
Other data collected includes:  
Demographics including  height (baseline only), weight and Hoehn and Yahr stage (at 
baseline and 12 months);(24) Parkinson’s medication; Abbreviated Mental Test(44) 
(intervention arms only), therapy logs including home-based therapy diaries, NHS therapy 
notes and a global rating scale (transition Item). 
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Adverse Events 
A risk assessment of the PD COMM trial has been performed with the SLT interventions 
considered to be of low risk. From the literature, the only reported adverse event (AE) 
associated with the interventions was a small increased risk of vocal strain or abuse, however 
none were reported in the PD COMM Pilot trial. This risk will be minimised: speech and 
language therapists are trained to identify and rehabilitate vocal strain so, if present, the 
therapist will be able to identify and address it. No other risks are expected to arise from 
taking part in the trial. It is therefore reasonable to collect only targeted AEs.  
 
For participants in either therapy arm, any vocal strain or abuse believed to be associated with 
treatment will be identified by the therapists at the participants’ therapy session and will be 
reported in the AE log.  
 
In all trial arms, BCTU will also check the participant reported resource usage form to ensure 
that no vocal strain or abuse has occurred following participants reporting out-patients 
appointments with ear, nose and throat (ENT) specialists. At the 12 month clinical visit, the 
medical professional will also check whether any AEs have occurred since entering the trial. 
 
Serious adverse events (SAEs) are events that cause death, are life threatening, require or 
extend an existing hospitalisation, results in persistent or significant disability or incapacity; 
or, is otherwise considered medically significant by the Investigator.  SAEs that are not 
related to vocal strain or abuse are excluded from expedited notification during the course of 
the trial and will be collected in the resource usage and 12 month clinical case report form.  
 
Data Collection 
Data is collected in clinic at baseline and 12 months post-randomisation at usual clinic 
appointments, and patient-reported outcome data which is also collected at 3, 6 and 12 
months post-randomisation by postal questionnaires to the participant and are returned 
directly to BCTU. Participants who do not comply with their treatment allocation will be 
followed up as other participants unless they chose to withdraw from the trial. Data is 
reviewed on receipt, and return rates and completeness are closely monitored throughout the 
trial to ensure patient retention. The Trial Management Group review return and 
completeness rates and can determine whether to trigger further review or monitoring. 
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 Figure 1 provides a flowchart of the trial design and table 2 denotes the schedule of events. 
Data are sent to BCTU where they are securely held in restricted access areas and entered 
onto a bespoke trial database. For participants randomised to the intervention arms, further 
data around the interventions including therapy logs and therapy notes are sent to BCTU (see 
below). Redacted therapy notes and anonymised data sets will be sent to researchers at 
Glasgow Caledonian University for the intervention description analysis. These data will be 
integrated with the process evaluation data collected and held at the University of Bangor. 
[Insert Figure 1 here] 
[Insert table 2 here] 
 
Treatment Dose and Fidelity 
The speech and language therapists will complete an initial interview log including the 
Abbreviated Mental Test and intervention record forms at each treatment session for 
participants receiving SLT. Furthermore, in the LSVT LOUD® arm and where prescribed in 
the NHS SLT arm, participants will complete home-based therapy diaries. Therapists will 
also complete standard NHS therapy notes; upon trial treatment completion, a pseudo-
anonymised (i.e. participant only identified by trial number) version of these will be sent to 
the research team.   
 
Process Evaluation  
In order to evaluate the implementation of PD COMM interventions, a process evaluation 
will be carried out alongside PD COMM. The process evaluation team led by Bangor 
University will employ a number of approaches to data collection, including:  
 Qualitative interviews with PD COMM participants 
 Qualitative interviews with PD COMM therapists 
 Critical incident reports 
 Therapists questionnaire 
 
A detailed protocol for these analyses including intervention description has been 
published(45)  
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The analysis of process evaluation data will focus on the practical implementation of the trial 
interventions, including how these were tailored to individual patient and other 
circumstances.  
 
Sample Size 
The primary outcome is the mean difference in the VHI total score at 3 months across the 
three comparisons: LSVT LOUD® versus control; standard NHS SLT versus control; and 
LSVT LOUD® versus standard NHS SLT. Data from the PD COMM pilot trial was used to 
inform the sample size calculations for this trial as the minimal clinically important 
difference (MCID) for the VHI has not been established in Parkinson’s patients. In the PD 
COMM pilot trial, a difference of around 10 points in VHI total score was observed at 3 
months between SLT and control for both types of SLT (standard NHS and LSVT LOUD®) 
versus control comparisons. To detect a 10-point difference in VHI total score between arms 
at 3 months (using a 2-sided t-test and the upper standard deviation of 26.27 obtained from 
the VHI baseline data from the pilot trial; effect size 0.38), with 80% power and α=0.01, we 
need 163 participants per arm. Allowing for 10% drop-out will require 182 participants per 
arm, so 546 participants in total.  
 
Statistical Analysis 
All primary analyses (for both the primary and secondary outcomes) will be by intention to 
treat. Participants will be analysed in the treatment group to which they were randomised, and 
all participants shall be included whether or not they received the allocated treatment. This is 
to avoid any potential bias in the analysis. For all tests, summary statistics (e.g. mean 
differences) will be reported along with 95% confidence intervals and p-values from two-
sided tests. A p-value of <0.01 will be considered statistically significant, as per the sample 
size calculations to take into account the multiple treatment comparisons being undertaken.  
There will be no interim analyses 
The analysis and interpretation of qualitative data, and its integration with quantitative data 
on intervention provision, will be performed between researchers at Bangor University 
(Professor Christopher Burton) and Glasgow Caledonian University (Professor Marian 
Brady), with input from University College London (Dr Christina Smith) and King’s College 
London (Professor Cath Sackley).  
 
Primary Outcome Analysis 
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The primary outcome measure is the VHI total score at 3 months. A linear regression model 
will be used to estimate differences in the VHI total score at 3 months between the two arms 
of interest, with the VHI baseline score and the minimisation variables age and severity of 
Parkinson’s (Hoehn & Yahr) included in the model as covariates.  
 
Secondary Outcome Analyses 
The majority of the secondary outcome measures (e.g. PDQ-39) are continuous 
measurements and will be analysed in a similar way to that described for the primary 
analysis: a linear regression analysis adjusting for relevant baseline score and all of the 
minimisation variables (baseline VHI, age and severity of PD). As per the primary outcome, 
the primary analysis for the secondary outcomes will be based on the 3 month data. 
 
To assess whether any treatment effect is maintained, participant and carer completed 
questionnaires are also being collected at 6 and 12 months post-randomisation. Data collected 
at 6 and 12 months will be analysed using the same methods as described above. Further 
analysis using a repeated measures model will also be performed using all data over the 3, 6 
and 12 month assessment points. 
 
A Global rating scale (transition item) will be completed by the participant and carer 
separately at the 3 month time point. These data will be used to calculate an MCID for the 
VHI in this population. 
 
Adverse events and safety data will be summarised descriptively by treatment arm, and the 
number of events and percentage of participants experiencing any adverse event reported. It 
is not expected that there will be many adverse events as a result of the intervention, but the 
number of participants reporting an adverse event will be compared using a Chi-squared test, 
with relative risks and 95% confidence intervals reported (if appropriate). 
 
Planned Subgroup Analyses 
Subgroup analyses will be performed for the primary outcome to assess whether there are 
differences in treatment effect by the minimisation variables: age; baseline voice severity (as 
measured by VHI); and Parkinson’s severity (as measured by Hoehn & Yahr). The trial is not 
powered to detect differences in treatment effect in these subgroups and therefore these 
analyses will be treated as purely hypothesis generating. 
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Health Economics Analysis 
The economic evaluation will estimate the cost-effectiveness of LSVT LOUD® or standard 
NHS SLT compared to no SLT treatment (control) in Parkinson’s. The base-case economic 
evaluation will be undertaken from the UK NHS and personal social services (PSS) 
perspective, with further analysis from a broader societal perspective, over 12 months follow 
up.  
 
A cost-effectiveness analysis will use the primary outcome (VHI) to calculate the cost per 
unit improvement in VHI score, and a cost-utility analysis will use responses from the EQ-
5D-5L to calculate cost per quality-adjusted life year (QALY) gained. Resource use data will 
be collected on Parkinson’s-related medication, primary care and secondary care healthcare 
utilisation, including the use of therapy services, and use of social services including formal 
care. Further information will be collected on time off work, participant out of pocket costs 
and costs incurred by informal carers, in order to inform analysis from a societal perspective. 
The cost of delivering the LSVT LOUD® intervention and NHS SLT, including length and 
number of sessions and any training required will be determined within the trial. Data will be 
collected using a participant-completed resource utilisation questionnaire (at 3, 6 and 12 
months) and the therapist-completed Initial Interview Logs and Treatment Record Forms. 
Unit costs from routine sources will be applied to resource use data.(46, 47) Health related 
quality of life will be assessed using the EQ-5D-5L(41) collected at baseline, 3, 6 and 12 
months. The crosswalk value set will be applied to patient responses to obtain utility scores, 
in line with current NICE recommendations and QALYs calculated using “area under the 
curve” approach. The ICECAP-O(42) will also be used to capture changes in participants’ 
capabilities, allowing a broader assessment of benefits to patients.  
 
 Incremental cost-effectiveness and cost-utility analyses will be undertaken to estimate the 
incremental cost per unit of outcome gained, adjusting for baseline covariates. Two sets of 
comparisons will be undertaken. In line with convention, strategies will be ordered from least 
to greatest cost, with each strategy compared against the next more costly strategy, and 
strategies which are dominated or extendedly dominated subsequently excluded. A separate 
analysis will also consider the three pair-wise comparisons as specified in the statistical 
analysis. Both deterministic and probability sensitivity analysis will be undertaken and cost-
effectiveness acceptability curves will be produced to reflect the probability the intervention 
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will be cost-effective at different willingness to pay thresholds, in terms of cost per unit of 
outcome gained. 
 
Dissemination 
The trial results will be disseminated widely through scientific conferences and peer reviewed 
publications. Collaborators will be informed of the trial results at a national trial results 
meeting and participants will be sent a newsletter thanking them for their support and 
informing them of the trial results. We will also use social media and work with the 
Universities media services, NIHR HTA dissemination services and the Parkinson’s UK 
charity to broaden our dissemination to key stake holders and the wider community. 
 
Roles and responsibilities 
The study design, collection, management, analysis and interpretation of the data, publishing 
the data is the responsibility of the Chief Investigator, and the collaborative group, the trial is 
managed by the Birmingham Clinical Trials Unit, with additional support for Scottish sites 
being provided by Glasgow Caledonian University. The process evaluation is managed by the 
University of Bangor and the intervention description analysis is managed by Glasgow 
Caledonian University.  The Sponsor and Funder do not have a role in the above activities.  
 
Oversight of the trial is performed by the Trial Management Group, an independent Data 
Monitoring Committee (DMC) and Trial Steering Committee (TSC). The DMC and TSC 
membership (see table 3) was agreed with the Funder, these committees meet at least 
annually to review the data and progress of the trial. Annual reports are submitted to the NHS 
REC and monthly updates against pre-determined milestones are sent to the funder.  
 
[Insert table 3 here] 
Discussion 
The PD COMM trial is already the largest trial of SLT in Parkinson’s to date (as of 10th 
September 2019, 329 participants have been recruited). It will provide robust evidence as to 
the effectiveness and cost effectiveness of two types of SLT for people with Parkinson’s 
enabling them, their clinicians and NHS decisions makers to make informed choices. 
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There will also be benefits beyond the immediate trial results: the group has developed a 
research network of speech and language therapists in 42 sites around the UK, participated in 
and provided training in LSVT LOUD® (courtesy of Dr Lori Ramig), trials, other aspects of 
Parkinson’s disease and research into SLT and information on best practice. This project will 
lay the foundation for further trials in SLT and lower barriers to future research. Furthermore, 
we will develop a clear understanding of the range of SLT practice around the UK for people 
with speech or voice problems as a consequence of Parkinson’s, in terms of dosage, content 
and availability.  
 
Trial Status 
Protocol version number and date: version 4.0 (14th November 2018) 
The first participant was recruited into the trial on 11th October 2016. Recruitment is ongoing 
with an expected recruitment end date of 30th November 2020. 
 
Declarations: 
Ethical Approval and Consent to Participate 
The trial received ethical approval from the West Midlands NHS Research Ethics Committee 
(15/WM/0443) prior to all trial activity at NHS Sites.  The ethical approval covers all 
participating centres. All participants in the trial will provide informed consent prior to any 
trial procedure. 
Consent for Publication 
Not applicable – no individual’s data included 
Funding Acknowledgement and Disclaimer 
This study is funded by the National Institute of Health Research (NIHR) Health Technology 
Assessment programme (HTA:10/135/02). The views expressed are those of the authors and 
not necessarily those of the NIHR or the Department of Health and Social Care. The study 
design, collection, management, analysis and interpretation of the data, publishing the data is 
the responsibility of the Chief Investigator, and the collaborative group, the funder does not 
have a role in the above. 
Availability of Data 
Following the publication of the main trial results anonymous data sets will be available on 
an individual case by case basis in accordance with the University of Birmingham, 
Birmingham Clinical Trials Unit’s Standard Operating Procedures with agreement from Prof 
Catherine Sackley and King’s College, London. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
20 
 
Competing Interests 
The authors declare that they have no competing interests. 
 Authors’ Contributions 
Authors CS, MB, CB, CC, NI, CJ, SP, CR, and CHS made substantial contributions to the 
conception and design of the trial. Authors PA, GB, MC, SD, FD, MH, PMA, and AN, made 
substantial contributions to the acquisition of data. All authors are key to the management, 
and ongoing oversight of the trial. Author CR drafted the work and all authors read, edited 
and approved the final manuscript. 
 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
Protocol Amendments 
Original application: v1.0 Protocol and participant CRFs.  Protocol approved subjected to 
minor changes. Resubmitted to REC and approved as v1.1 07.12.2015. 
Amendment 3: update to protocol 2.0, consent form, participant information sheet and 
questionnaires. 
Amendment 10: update to protocol 4.0, participant & carer consent form, participant & carer 
info sheet and participant CRFs.  Creation of letter to accompany PIS (if posting), patient 
leaflet and poster. 
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The PD COMM Collaborative Group 
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Mohamed, S Mahon, T Williams, S Appleton, N Elliott, L Evans, J Ridley,   
Central London Community Healthcare NHS Trust: A Funaki*, P Daly, J Hackworth, K 
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Pegler, C Drayson, P Turner, J Stockwell;   
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Johnson, H Thornley, S Conway;   
Hywel Dda University Health Board: C James*, S Murrow, M Hughes, K Pope, C 
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Leeds Teaching Hospitals NHS Trust: I Mavroudis*, J Alty#, E Richfield, J Harrison, V 
Smith, T Joyce, J Bamford, S Jamieson, J Cosgrove, S Butterworth, E Sacre, L Makawa, P 
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Table 1: Participating Sites and Principal Investigators 
Trust PI 
Aneurin Bevan University Health Board Alistair Church 
Basildon and Thurrock University Hospitals NHS Foundation 
Trust 
Sigurlaud Sveinbjornsdottir 
Betsi Cadwaladr University Health Board Sam Abraham 
Blackpool Teaching Hospitals NHS Foundation Trust David McGhee 
Brighton & Sussex University Hospitals NHS Trust Romi Saha 
Cardiff and Vale University Health Board Chris Thomas 
Central London Community Healthcare NHS Trust Ayano Funaki 
East Cheshire NHS Trust Monty Silverdale 
Gloucestershire Hospitals NHS Foundation Trust Sangeeta Kulkarni 
Great Western Hospitals NHS Foundation Trust Graham Lennox 
Guy's and St Thomas' NHS Foundation Trust Thomasin Andrews 
Harrogate and District NHS Foundation Trust Rosaria Buccoliero 
Heart of England NHS foundation Trust (Now University 
Hospitals Birmingham NHS Foundation Trust) 
Martha Pinkney 
Homerton University Hospital NHS Foundation Trust Laetitia Sautin 
Hywel Dda University Health Board Christopher James 
Lancashire Teaching Hospitals NHS Trust Tahir Majeed 
Leeds Teaching Hospitals  NHS Trust Ioannis Mavroudis 
London North West Healthcare NHS Trust Judy Anne Juada 
NHS Ayrshire and Arran Andrew Watt 
NHS Dumfries & Galloway Shona Donaldson 
NHS Forth Valley Suvankar Pal 
NHS Greater Glasgow and Clyde Steven Wishart 
NHS Highland / Argyll and Bute Martin Wilson 
NHS Lanarkshire Helen Morgan 
NHS Lothian Gordon Duncan 
NHS Tayside Derek Sutherland 
Norfolk and Norwich University Hospitals NHS Trust Stephanie Cooper 
Norfolk Community Health and Care NHS Trust Lauren Issacs 
North Bristol NHS Trust Alan Whone 
Northern Lincolnshire and Goole NHS Foundation Trust Shankar Kamath 
Pennine Acute Hospitals NHS Trust Jason Raw 
Powys Teaching UHB Jane Price 
Royal Devon & Exeter NHS Foundation Trust Ray Sheridan 
Sandwell and West Birmingham Hospitals NHS Trust Carl Clarke 
St Helens And Knowsley Hospitals NHS Trust Dipen Gandecha 
Taunton and Somerset NHS Foundation Trust Simon Cooper 
The Walton Centre NHS Foundation Trust Malcolm Steiger 
Torbay and South Devon NHS Foundation Trust Rachel Nashed 
University Hospitals Bristol NHS Foundation Trust Theresa Allain 
University Hospitals of South Manchester NHS Foundation 
Trust (now Manchester University NHS Foundation Trust) 
David Ahearn 
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Bath and North East Somerset Community Health and Care 
Services NHS 
Veronica Lyell 
Wye Valley NHS Trust Emma Wales 
 
 
Table 2: Time and Event Schedule 
Measure  Assessment time 
 Enrolment 
Allocation 
t = 0 
3 
months 
6 
months 
12 
months 
Enrolment      
Informed Consent      
Eligibility       
Allocation      
Interventions      
Initial Interview Log and 
Treatment Record Form 
(all sessions) 
  *  
 
Home-Based Therapy 
Diary 
  **  
 
Assessments      
Baseline Case Report Form      
VHI; PDQ-39; QASD; EQ-
5D-5L; ICECAP-O 
     
Resource Usage 
Questionnaire 
     
Global Rating Score 
(Transition Item) 
     
PDQ-Carer      
Adverse Event Log   ***   
12 month Case Report 
Form 
     
* Following each therapy session for participants in the two SLT treatment arms only. 
** Completed at home by the participant as recommended in their SLT therapy session. 
*** Only required for participants randomised to a treatment arm.  
 
 
 
 
Table 3: Trial Oversight Committees 
Trial Management Group Data Monitoring Committee 
Prof. Cath Sackley (Chief 
Investigator)  
Dr Carl Counsell (Chair), Consultant Neurologist, 
University of Aberdeen. 
Ms Pui Au 
Ms Gillian Beeston  Dr Katherine Deane, Senior Lecturer, University of 
East Anglia. Prof. Marian Brady  
Prof. Christopher Burton   Dr Louise Hiller, Statistician, University of Warwick. 
Ms Maria Caulfield   
Prof. Carl E Clarke  Trial Steering Committee 
Ms Sylvia Dickson Dr Lisa Shaw (Chair), Senior Research Associate, 
University of Newcastle upon Tyne.  Dr Sue Jowett 
Dr Patricia Masterson Algar Mr Chris Jeffery, Patient and Public Involvement 
Representative.  Dr Avril Nicoll 
Mrs Smitaa Patel  Ms Michelle Collinson, Senior Medical Statistician, 
University of Leeds.  Dr Cally Rick 
Mrs Natalie Rowland  Dr Linsay Pennington, Senior Lecturer and Speech 
and Language Therapist, University of Newcastle 
upon Tyne.  
Dr Christina Smith  
Ms Rebecca Woolley  Prof. Cath Sackley, Professor of Rehabilitation, 
King’s College London.    
Former Members Dr Paul Worth, Consultant in Neurology, Cambridge 
University Hospitals NHS Foundation Trust. Mr Francis Dowling 
Mr Max Hughes   
  Former Member: 
  
Mr John Carrington, Patient and Public Involvement 
Representative. 
 
Prof. Adam Gordon, Professor in Medicine of Older 
People, University of Nottingham. 
 
Dr Simon Horton, Lecturer and Speech and 
Language Therapist, University of East Anglia. 
  
Figure 1: Flow Diagram of Trial Design 
 
Patients who have Parkinson’s and problems with their speech 
or voice are identified by physician, nurse or therapist 
Physician, nurse or therapist discusses trial and provides 
potential participant with Patient Information Sheet 
Physician, nurse or therapist confirm eligibility, answer any 
outstanding questions and take consent 
Following consent, baseline assessments are performed, and 
then the participant is randomised in to the trial 
LSVT No SLT (Control) 
3, 6 and 12 month follow-up assessments 
Complete trial 
Standard NHS  
SLT 
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* 
Section/item Item 
No 
Description Addressed on 
page number 
Administrative information 
 
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym _____1________ 
Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry _____4________ 
2b All items from the World Health Organization Trial Registration Data Set _____y________ 
Protocol version 3 Date and version identifier _____7________ 
Funding 4 Sources and types of financial, material, and other support _____7_          _ 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors _____1________ 
5b Name and contact information for the trial sponsor ______7_______ 
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
 
______18_______ 
 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
 
 
 
_____18________ 
EQUATOR Network Reporting Checklist (see Reporting Standards section for this article
type via the Information For Authors button above)
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 2 
Introduction 
   
Background and 
rationale 
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention 
_____5________ 
 6b Explanation for choice of comparators ______6-7_____ 
Objectives 7 Specific objectives or hypotheses _____7-8______ 
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory) 
 
____7_________ 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained 
____8_________ 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, surgeons, psychotherapists) 
______8_______ 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 
administered 
_____9-11______ 
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or improving/worsening disease) 
_____11________ 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 
(eg, drug tablet return, laboratory tests) 
____11 (LSVT)___ 
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial ___N/A – no 
requirements 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended 
 
______11-13____ 
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 3 
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly recommended (see Figure) 
_____14 & fig 1__ 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 
clinical and statistical assumptions supporting any sample size calculations 
______15______ 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size ______8_______ 
Methods: Assignment of interventions (for controlled trials) 
 
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants 
or assign interventions 
______9_______ 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 
____9_________ 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 
interventions 
______9_______ 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
N/A_- no blinding_ 
 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
N/A – no blinding_ 
Methods: Data collection, management, and analysis 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
_____13-14_____ 
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 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
_____13-14_____ 
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
procedures can be found, if not in the protocol 
_____13________ 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 
statistical analysis plan can be found, if not in the protocol 
_____15-17_____ 
 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) _____16________ 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple imputation) 
 
_____15-16_____ 
Methods: Monitoring 
 
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
_____Table 3___ 
 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
_N/A_- none 
planned_ 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
_____13________ 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
_____13________ 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval _____7_______ 
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Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
____18_________ 
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32) 
______y_______ 
 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
studies, if applicable 
_N/A_- no samples 
taken_ 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained 
in order to protect confidentiality before, during, and after the trial 
___22 & consent 
forms__ 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each study site ____22_________ 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that 
limit such access for investigators 
____22_________ 
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial 
participation 
_N/A – no 
provision. 
interventions are 
routine care___ 
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
_____18________ 
 31b Authorship eligibility guidelines and any intended use of professional writers _N/A_- no 
professional 
writers______ 
 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code _____22_______ 
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Informed consent 
materials 
32 Model consent form and other related documentation given to participants and authorised surrogates ____Y_________ 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
_N/A – no 
samples_ 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. 
Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons 
“Attribution-NonCommercial-NoDerivs 3.0 Unported” license. 
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